ImmunityBio (IBRX) Receivables (2014 - 2026)

ImmunityBio (IBRX) has 8 years of Receivables data on file, last reported at $43.3 million in Q1 2026.

• On a quarterly basis, Receivables rose 153.14% year-over-year to $43.3 million in Q1 2026; TTM through Mar 2026 was $43.3 million, a 153.14% increase from a year earlier, with the FY2025 full-year figure at $42.6 million, up 1564.73% from the prior year.
• Receivables for Q1 2026 stood at $43.3 million, up from $42.6 million in the prior quarter.
• Over the last five years, Receivables for IBRX reached as high as $43.3 million in Q1 2026 and fell as low as $2.0 million in Q4 2023.
• Historically, Receivables has averaged $14.1 million across 5 years, with a median of $3.6 million in 2023.
• Across the five-year window, Receivables plunged 36.71% in 2023 and surged 1564.73% in 2025, its largest moves.
• Year by year, Receivables stood at $3.2 million in 2022, then plunged by 36.71% to $2.0 million in 2023, then climbed by 26.8% to $2.6 million in 2024, then jumped by 1564.73% to $42.6 million in 2025, then increased by 1.54% to $43.3 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $43.3 million in Q1 2026, $42.6 million in Q4 2025, and $33.7 million in Q3 2025.